• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 15th May 2020

In Memoriam Adam Wagstaff 1959-2020

On the occasion of Adam Wagstaff’s death, Professor Tony Culyer reflects on his vast legacy to health economics, from Tony’s perspective of having been Adam’s PhD supervisor as well as a friend and collaborator. On the occasion of Adam Wagstaff’s…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

On the occasion of Adam Wagstaff’s death, Professor Tony Culyer reflects on his vast legacy to health economics, from Tony’s perspective of having been Adam’s PhD supervisor as well as a friend and collaborator.

On the occasion of Adam Wagstaff’s death on May 10th, 2020, OHE pays tribute to his legacy with an obituary written by Professor Tony Culyer.

Adam Wagstaff, despite having just turned 61 years of age, leaves behind him seminal contributions to health economics. He greatly increased our understanding of: the demand for health and health production (see Wagstaff’s diagram of Grossman’s model, for instance); issues of health, poverty and the measurement of equity; the importance of universal health care; the efficient financing of health systems; health valuation; and much more.

Obituary by Tony Culyer:

It is a rare privilege to supervise DPhil students of such exceptional talent as Adam possessed, yet it’s one that fell to me, so I am immensely proud to have counted him as a friend and I am, vicariously, no less proud of all he has achieved. He was my brightest doctoral supervisee. As anyone who knew him would know, he needed next to no management, was never at a loss for an idea fit for the occasion, assiduous in his commitment to economics, diligent in all he undertook, imaginative in using the economics way of thinking and always keen to share his ideas through writing, workshops, talks and blogs. A dream student one would think – but no, at least not in the sense that he was easy. Adam challenged one. In the community of scholars, the university, what Jacques Barzun called “the House of Intellect” [1], he was hard work. His logic always relentless. His opinions evidenced. His attention to detail pedantic. But his attention to detail never came at the cost of the bigger picture. He often knew better what I had written than I did myself! His was a mind born to tackle serious questions of morality in public policy.  He made his teachers think – and rethink. That was what made him hard work and that, of course, is what made him an ideal colleague. I think it is as a colleague that I always thought of him, right from the beginning. Given who and what he was, it is hardly to be wondered at that he reached the pinnacle of his career at another House of Intellect: The World Bank, in which intellects and their application to relieve a suffering world are perfectly combined.

It was not surprising that our first joint publications were while Adam was still a postgraduate student at York [2, 3]. These were ad hoc (commercially funded) early cost-effectiveness studies with one or two ingenious twists that were down to him. I think they were honestly done. Equity was, however, the principal territory that kept us in touch when he had left both York and Sussex. It culminated for me in our joint paper [4], which must have been one of the last flowerings of economic geometry in economic literature. Thereafter, I became increasingly absorbed in university management, while he built his astonishing global health equity network, out of which a thousand PhD theses have doubtless been born. He had the charisma, enthusiasm, acumen, and organisational talent to make that network happen and, in the process, to bring into being an international league of friends and colleagues that must be second to none. Such were the working relationships he had that his very identity on at least one occasion merged with another’s: after years of writing with Eddy van Doorslaer he became “Adam van Wagstaff” in one paper [5: 409]!

His topical breadth was immense, though social concern remained at the heart of it all. His work led the world both theoretically and empirically: education economics, poverty, economics of social protection, health systems and their reform, the place of health in welfare economics, health insurance and the delivery of Universal Health Coverage in low and middle income countries, transitions and inequities that arise from threshold entitlements that violate the principle of horizontal equity, the demand for health and the demand for health care, incentives and the behaviour of agents in health care provision and health care policy, the measurement of health and associated inequalities of course, the pharmaceutical industry, bibliometry, health econometrics. In all cases, measurement was to the fore. He was never merely a fine theorist; his was theory that was there to be applied – and he applied it.

To teach and, later, to work with Adam was to engage with someone whose personality showed an unlikely combination of diffidence and self-confidence: diffidence in that he never bullied or relished intellectual aggression in debate or argument; self-confidence in that he held his ground tenaciously, with rigour, and pursued the case to the very end. There was never much doubt about who had won, but at least losing left few scars!

We have lost a very nice man and a wonderful scholar.

Tony Culyer

Emeritus Professor of Economics, University of York, UK

 

References

1. J Barzun, The House of Intellect, HarperCollins, 1959.

2. A J Culyer, J MacFie, A Wagstaff, “Cost-effectiveness of foam elastomer and gauze dressings in the management of open perineal wounds”, Social Science and Medicine, 1983, 17: 1047-53.

3. A J Culyer, A Wagstaff, J MacFie, “Foam elastomer and gauze dressings in the management of open perineal wounds: a cost-effectiveness study”, British Journal of Clinical Practice, 1984, 38: 263-8.

4. A J Culyer, A Wagstaff,  “Equity and equality in health and health care”, Journal of Health Economics, 1993, 12:  431-457 (reprinted in N Barr (ed.) Economic Theory and the Welfare State, Cheltenham: Edward Elgar, 2001, 231-257.

5. A Wagstaff, A J Culyer, “Four decades of health economics through a bibliometric lens”, Journal of Health Economics, 2012, 31: 406-39.

  • Healthcare Systems

Related Insights

Air balloon HTA v4
  • Insight
  • March 2023

Around The World in HTAs: Spain – Are We There Yet?

Read more
Informal Carer Burden Series: OHE on behalf of Roche
  • Insight
  • March 2023

Caring about Carers: Improving Consideration of the Burden of Informal Caring in HTA

Read more
Eye-Disease Gene-Therapies blog
  • Insight
  • February 2023

Cost-effectiveness Analysis of Gene Therapies for Inherited Eye Disease: Are Current Discounting Approaches Too Short-sighted?

Read more
Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!